Suppr超能文献

使用阿尔茨海默病新诊断标准及疾病相关生物标志物对记忆门诊的非痴呆患者进行分类。

Classification of non-demented patients attending a memory clinic using the new diagnostic criteria for Alzheimer's disease with disease-related biomarkers.

作者信息

Ivanoiu Adrian, Dricot Laurence, Gilis Nathalie, Grandin Cécile, Lhommel Renaud, Quenon Lisa, Hanseeuw Bernard

机构信息

Neurology Department, Saint Luc University Hospital, Université catholique de Louvain, Brussels, Belgium Institute of Neuroscience, Université catholique de Louvain, Brussels, Belgium.

Institute of Neuroscience, Université catholique de Louvain, Brussels, Belgium.

出版信息

J Alzheimers Dis. 2015;43(3):835-47. doi: 10.3233/JAD-140651.

Abstract

BACKGROUND

New diagnostic criteria for predemential Alzheimer's disease (AD) advocate the use of biomarkers. However, the benefit of using biomarkers has not been clearly demonstrated in clinical practice.

OBJECTIVE

To investigate whether a combination of biomarkers may be helpful in classifying a population of non-demented patients attending a Memory Clinic.

METHODS

Sixty non-demented patients were compared with 31 healthy elderly subjects. All subjects underwent a neuropsychological examination, brain 3T magnetic resonance imaging, [F18]-fluorodeoxyglucose and [F18]-flutemetamol positron emission tomography. According to their performance on memory, language, executive, and visuo-spatial domains, the patients were classified as mild cognitive impairment (amnestic, non-amnestic, single, or multiple domain) or subjective cognitive impairment. Patients were then classified according to the National Institute on Aging-Alzheimer's Association (NIA-AA) criteria, using the normalized mean hippocampal volume (Freesurfer), [F18]-FDG PALZAD, and [F18]-flutemetamol standard uptake value ratio (SUVr) (cut-off at the 10th percentile of controls). The standard of truth was the clinical status at study entry (patient versus control).

RESULTS

The sensitivity/specificity of the clinical classification was 65/84%. The NIA-AA criteria were applicable in 85% of patients and 87% of controls. For biomarkers the best sensitivity (72%) at a fixed specificity of 84% was achieved by a combination of the three biomarkers. The clinical diagnosis was reconsidered in more than one third of the patients (42%) as a result of including the biomarker results.

CONCLUSIONS

Application of the new NIA-AA AD diagnostic criteria based on biomarkers in an unselected sample of non-demented patients attending a Memory Clinic was useful in allowing for a better classification of the subjects.

摘要

背景

早期阿尔茨海默病(AD)的新诊断标准提倡使用生物标志物。然而,在临床实践中使用生物标志物的益处尚未得到明确证明。

目的

研究生物标志物组合是否有助于对就诊于记忆门诊的非痴呆患者群体进行分类。

方法

将60名非痴呆患者与31名健康老年受试者进行比较。所有受试者均接受了神经心理学检查、脑部3T磁共振成像、[F18] - 氟脱氧葡萄糖和[F18] - 氟替美莫正电子发射断层扫描。根据患者在记忆、语言、执行和视觉空间领域的表现,将患者分类为轻度认知障碍(遗忘型、非遗忘型、单一或多领域)或主观认知障碍。然后根据美国国立衰老研究所 - 阿尔茨海默病协会(NIA - AA)标准,使用标准化平均海马体积(FreeSurfer)、[F18] - FDG PALZAD和[F18] - 氟替美莫标准摄取值比率(SUVr)(以对照组第10百分位数为临界值)对患者进行分类。金标准是研究入组时的临床状态(患者与对照)。

结果

临床分类的敏感性/特异性为65/84%。NIA - AA标准适用于85%的患者和87%的对照。对于生物标志物,在固定特异性为84%时,三种生物标志物组合可实现最佳敏感性(72%)。由于纳入了生物标志物结果,超过三分之一的患者(42%)的临床诊断被重新考虑。

结论

在就诊于记忆门诊的未选择的非痴呆患者样本中应用基于生物标志物的新NIA - AA AD诊断标准有助于对受试者进行更好的分类。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验